Applications of TALENs and CRISPR/Cas9 in human cells and their potentials for gene therapy

Molecular Biotechnology

Volumn 56, Issue 8, 2014, Pages 681-688

  Niu, Jingwen ^a   Zhang, Bin ^a   Chen, Hu ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

CCR5; CRISPR Cas9; Gene therapy; Genome editing; TALENs

Indexed keywords

CYTOLOGY; GENE THERAPY;

CCR5; CRISPR/CAS9; GENOME ENGINEERING; HUMAN CELLS; SITE-SPECIFIC; TALENS; WORKING MECHANISMS;

CELLS;

NUCLEASE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5;

CCR5 GENE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE LOCUS; GENE TARGETING; GENETIC ENGINEERING; GENETIC MANIPULATION; HUMAN; HUMAN CELL CULTURE; RECEPTOR GENE; REVIEW; BIOLOGICAL MODEL; BIOTECHNOLOGY; CRISPR CAS SYSTEM; DNA REPAIR; GENE THERAPY; GENETICS; PROCEDURES; RNA EDITING;

BIOTECHNOLOGY; CRISPR-CAS SYSTEMS; DNA REPAIR; GENE TARGETING; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; MODELS, GENETIC; RECEPTORS, CCR5; RNA EDITING;

EID: 84904857603     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-014-9771-z     Document Type: Review

References (61)

1. Verma, I. M., & Weitzman, M. D. (2005). Gene therapy: Twenty-first century medicine. Annual Review of Biochemistry, 74, 711-738. (Pubitemid 40995522)
2. Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., et al. (2008). Establishment of HIV-1 resistance in CD4+T cells by genome editing using zinc-finger nucleases. Nature Biotechnology, 26, 808-816. (Pubitemid 351961450)
3. Li, L., Krymskaya, L., Wang, J., Henley, J., Rao, A., Cao, L.-F., et al. (2013). Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Molecular Therapy, 21, 1259-1269.
4. Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., & Cathomen, T. (2011). A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Research, 39, 9283-9293.
5. Ding, Q., Lee, Y.-K., Schaefer, E. A., Peters, D. T., Veres, A., Kim, K., et al. (2012). A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell, 12, 238-251.
6. Takata, M., Sasaki, M. S., Sonoda, E., Morrison, C., Hashimoto, M., Utsumi, H., et al. (1998). Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. The EMBO Journal, 17, 5497-5508. (Pubitemid 28427063)
7. Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., et al. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. Genetics, 186, 757-761.
8. Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., et al. (2010). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology, 29, 143-148.
9. Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S., Gao, Q., Cassady, J. P., et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nature Biotechnology, 29, 731-734.
10. Li, T., Huang, S., Jiang, W. Z., Wright, D., Spalding, M. H., Weeks, D. P., et al. (2011). TAL nucleases (TALNs): Hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Research, 39, 359-372.
11. Santiago, Y., Chan, E., Liu, P.-Q., Orlando, S., Zhang, L., Urnov, F. D., et al. (2008). Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proceedings of the National Academy of Sciences, 105, 5809-5814. (Pubitemid 351758454)
12. Bogdanove, A. J., & Voytas, D. F. (2011). TAL effectors: Customizable proteins for DNA targeting. Science, 333, 1843-1846.
13. Moehle, E. A., Rock, J. M., Lee, Y.-L., Jouvenot, Y., DeKelver, R. C., Gregory, P. D., et al. (2007). Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proceedings of the National Academy of Sciences, 104, 3055-3060. (Pubitemid 46364112)
14. Gaj, T., Gersbach, C. A., & Barbas III, C. F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology, 31, 397-405.
15. Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., et al. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 326, 1509-1512.
16. Bogdanove, A. J., Schornack, S., & Lahaye, T. (2010). TAL effectors: Finding plant genes for disease and defense. Current Opinion in Plant Biology, 13, 394-401.
17. Moscou, M. J., & Bogdanove, A. J. (2009). A simple cipher governs DNA recognition by TAL effectors. Science, 326, 1501.
18. Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169, 5429-5433. (Pubitemid 18017837)
19. Horvath, P., & Barrangou, R. (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science, 327, 167-170.
20. Bhaya, D., Davison, M., & Barrangou, R. (2011). CRISPR-Cas systems in bacteria and archaea: Versatile small RNAs for adaptive defense and regulation. Annual Review of Genetics, 45, 273-297.
21. Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., et al. (2013). Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature Biotechnology, 31, 227-229.
22. Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013). RNA-guided editing of bacterial genomes using CRISPRCas systems. Nature Biotechnology, 31, 233-239.
23. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., et al. (2013). RNA-guided human genome engineering via Cas9. Science, 339, 823-826.
24. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816-821.
25. Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., et al. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152, 1173-1183.
26. Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 154, 442-451.
27. Stroud, D. A., Formosa, L. E., Wijeyeratne, X. W., Nguyen, T. N., & Ryan, M. T. (2013). Gene knockout using transcription activator-like effector nucleases (TALENs) reveals that human NDUFA9 protein is essential for stabilizing the junction between membrane and matrix arms of complex I. Journal of Biological Chemistry, 288, 1685-1690.
28. Hu, R., Wallace, J., Dahlem, T. J., Grunwald, D. J., & O'Connell, R. M. (2013). Targeting human MicroRNA genes using engineered Tal-effector nucleases (TALENs). PLoS ONE, 8, e63074.
29. Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013). RNA-programmed genome editing in human cells. Elife, 2, e00471.
30. Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nature Biotechnology, 31, 230-232.
31. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339, 819-823.
32. Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., et al. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology, 31, 822-826.
33. Kim, Y., Kweon, J., Kim, A., Chon, J. K., Yoo, J. Y., Kim, H. J., et al. (2013). A library of TAL effector nucleases spanning the human genome. Nature Biotechnology, 31, 251-258.
34. Ding, Q., Regan, S. N., Xia, Y., Oostrom, L. A., Cowan, C. A., & Musunuru, K. (2013). Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell, 12, 393-394.
35. Wei, C., Liu, J., Yu, Z., Zhang, B., Gao, G., & Jiao, R. (2013). TALEN or Cas9-rapid, efficient and specific choices for genome modifications. Journal of Genetics and Genomics, 40, 281-289.
36. Yang, L., Guell, M., Byrne, S., Yang, J. L., De Los Angeles, A., Mali, P., et al. (2013). Optimization of scarless human stem cell genome editing. Nucleic Acids Research, 41, 9049-9061.
37. Streubel, J., Blücher, C., Landgraf, A., & Boch, J. (2012). TAL effector RVD specificities and efficiencies. Nature Biotechnology, 30, 593-595.
38. Sakuma, T., Ochiai, H., Kaneko, T., Mashimo, T., Tokumasu, D., Sakane, Y., et al. (2013). Repeating pattern of non-RVD variations in DNA-binding modules enhances TALEN activity. Scientific Reports, 3, 3379.
39. Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. Science, 343, 80-84.
40. Kim, E., Kim, S., Kim, D. H., Choi, B.-S., Choi, I.-Y., & Kim, J.-S. (2012). Precision genome engineering with programmable DNA-nicking enzymes. Genome Research, 22, 1327-1333.
41. Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnology, 31, 827-832.
42. Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nature Protocols, 8, 2281-2308.
43. Cho, S. W., Kim, S., Kim, Y., Kweon, J., Kim, H. S., Bae, S., et al. (2013). Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Research, 24, 132-141.
44. Ran, F., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., et al. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell, 154, 1380-1389.
45. Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013). High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnology, 31, 839-843.
46. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature Biotechnology, 32, 279-284.
47. Smith, A. M., Takeuchi, R., Pellenz, S., Davis, L., Maizels, N., Monnat, R. J., et al. (2009). Generation of a nicking enzyme that stimulates site-specific gene conversion from the I-AniI LAGL-IDADG homing endonuclease. Proceedings of the National Academy of Sciences, 106, 5099-5104.
48. Cade, L., Reyon, D., Hwang, W. Y., Tsai, S. Q., Patel, S., Khayter, C., et al. (2012). Highly efficient generation of heritable zebrafish gene mutations using homo-and heterodimeric TALENs. Nucleic Acids Research, 40, 8001-8010.
49. Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., et al. (2013). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology, 31, 833-838.
50. Pan, Y., Xiao, L., Li, A. S., Zhang, X., Sirois, P., Zhang, J., et al. (2013). Biological and biomedical applications of engineered nucleases. Molecular Biotechnology, 55, 54-62.
51. Bloom, K., Ely, A., Mussolino, C., Cathomen, T., & Arbuthnot, P. (2013). Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Molecular Therapy, 21, 1889-1897.
52. Ousterout, D. G., Perez-Pinera, P., Thakore, P. I., Kabadi, A. M., Brown, M. T., Qin, X., et al. (2013). Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients. Molecular Therapy, 21, 1718-1726.
53. Osborn, M. J., Starker, C. G., McElroy, A. N., Webber, B. R., Riddle, M. J., Xia, L., et al. (2013). TALEN-based gene correction for epidermolysis bullosa. Molecular Therapy, 21, 1151-1159.
54. Xu, L., Zhao, P., Mariano, A., Han, R. (2013). Targeted myostatin gene editing in multiple mammalian species directed by a single pair of TALE nucleases. Molecular Therapy - Nucleic Acids, 2, 112.
55. Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S., & Moraes, C. T. (2013). Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nature Medicine, 19, 1111-1113.
56. Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., et al. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 13, 653-658.
57. Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., et al. (1996). The b-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 85, 1135-1148. (Pubitemid 26231178)
58. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367-377. (Pubitemid 26272077)
59. Kim, H. J., Lee, H. J., Kim, H., Cho, S. W., & Kim, J.-S. (2009). Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Research, 19, 1279-1288.
60. Sakuma, T., Hosoi, S., Woltjen, K., Suzuki, K. I., Kashiwagi, K., Wada, H., et al. (2013). Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes to Cells, 18, 315-326.
61. Doench, G., & Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343, 84-87.